Alumis makes it through IPO window, but not without concessions
2024-06-28
IPO临床3期
Despite seemingly high investor interest, Alumis fell short of its original $300-million IPO goal. The inflammation-focused company sold far fewer shares than expected, and at the bottom of its proposed range, to raise $210 million – still enough to claim the title of year’s third-biggest biotech debut.
Coupled with a $40 million private placement from existing shareholder AyurMaya Capital Management Fund, Alumis raised a total of $250 million late Thursday.
Downsized offering
Alumis had been shooting for a sale of 17.7 million shares at $16 to $18 each, but the firm ended up only selling 13.1 million shares at $16 a piece.
The downsized offering comes after Australian radiopharmaceutical developer Telix pulled back from a planned NASDAQ IPO earlier this month, citing lower-than-desired pricing.
While the public markets have proven to be a rollercoaster for biotechs this year, Alumis’ $600 million in private funding — bolstered by a $259-million megaround in March – had seemed to indicate the firm had substantial investor interest to power a big ticket IPO. For more IPO analysis, see Vital Signs: Taking the temperature on a cooling IPO cycle.
Alumis is developing TYK2 inhibitorsTYK2 inhibitors to treat several autoimmune and neurodegenerative diseases. Its lead programme, ESK-001, is slated to start a Phase III study in plaque psoriasis in the second half, while mid-stage trials in uveitis and systemic lupus erythematosus are ongoing. The firm is also developing a brain-penetrant compound for multiple sclerosis.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。